Key result
Antipsychotic medications, particularly second-generation agents, were associated with an increased risk of venous thromboembolism in the context of the COVID-19 pandemic.
Why the study?
During the COVID-19 pandemic, a surge in psychiatric disorders and subsequent escalation in antipsychotic drug use raised concerns regarding associated thrombotic risks.
Does antipsychotic therapy increase the risk of venous thromboembolism, particularly during the COVID-19 pandemic?
Does antipsychotic therapy increase the risk of venous thromboembolism, particularly during the COVID-19 pandemic?
Antipsychotic medications, particularly second-generation agents, are associated with an increased risk of VTE, necessitating cautious prescribing during the COVID-19 pandemic.
Answers are grounded in this paper and cite their sources.
Possible antipsychotic-VTE links in COVID-19 warrant clinical awareness; leaves open causal confirmation in prospective studies.
In the context of the COVID-19 pandemic, this study investigates the potential correlation between the increased use of antipsychotic medications and the rising incidence of venous thromboembolism (VTE). As psychiatric disorders surged, the consequential escalation in antipsychotic drug use raised concerns about thrombotic risks. We conducted a comprehensive literature review using PubMed, focusing on articles that intersected COVID-19, antipsychotic medication, and thrombosis. This approach allowed for a nuanced examination of the historical and recent data on antipsychotic drugs and their association with thrombotic events. Our findings reveal a notable link between the use of antipsychotic medications, particularly second-generation antipsychotics, and an increased risk of VTE, including pulmonary embolism and deep vein thrombosis. This association was evident, despite variations in study designs and populations. The study underscores the need for cautious medication management in psychiatric care, especially during pandemic conditions like COVID-19, to mitigate thrombotic risks. It advocates a personalized approach to prescribing antipsychotics, considering individual patient factors and comorbidities, to balance the benefits against potential thrombotic complications.
No takes yet. Share an insight, caveat, or question.
Dho-Nagy et al. (2024) conducted a review in COVID-19 and psychiatric disorders. Antipsychotic medications was evaluated on Venous thromboembolism (VTE). Antipsychotic medications, particularly second-generation agents, were associated with an increased risk of venous thromboembolism in the context of the COVID-19 pandemic.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: